busy schedule, lets wait and see9 Mar 2018 13:23
Thu, 28th Sep 2017 07:00
RNS Number : 0275S
4d Pharma PLC
28 September 2017
Going forward
4D has a busy schedule of clinical trials coming up.
The next 12-18 months includes commencement of first-in-man trials in cancer and asthma, and commencement of the phase II trial for Blautix, as well as the conclusion of our phase I study in Paediatric Crohn's and commencement of a phase II study.
We will also continue our work in new fields, further exploring and understanding our efforts in areas such as neurodegeneration, and how our therapeutics can work alongside and potentially improve existing therapeutic approaches.
From inception in 2014, 4D has made solid progress. The Company has a class-leading platform which to date has generated 17 programmes across many disease areas. Two programmes have already been in patients and we have two first-in-man studies about to commence in cancer and asthma, and importantly 4D has the ability to develop, manufacture and deliver our products.
4D has a strong position to build on. We recognise that the field is still evolving, but we also recognise that 4D is leading its evolution.